

Haihong Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3867578/publications.pdf>

Version: 2024-02-01

13
papers

780
citations

1039880

9
h-index

1125617

13
g-index

13
all docs

13
docs citations

13
times ranked

993
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13103-13107.	3.3	591
2	Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein β -based DNA vaccine in tumor-bearing mice with murine breast carcinoma. Immunopharmacology and Immunotoxicology, 2017, 39, 37-44.	1.1	31
3	DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunology, Immunotherapy, 2012, 61, 1857-1867.	2.0	27
4	MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Vaccine, 2016, 34, 2648-2655.	1.7	23
5	Doxorubicin pretreatment enhances FAP β /survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model. OncoImmunology, 2020, 9, 1747350.	2.1	22
6	A DNA vaccine expressing an optimized secreted FAP β induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer. Vaccine, 2019, 37, 4382-4391.	1.7	21
7	MUC1 and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin β 2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model. Scandinavian Journal of Immunology, 2018, 87, 63-72.	1.3	19
8	Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect. Immunology Letters, 2018, 200, 33-42.	1.1	19
9	Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats. Human Immunology, 2008, 69, 250-258.	1.2	10
10	Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse. OncoImmunology, 2020, 9, 1841392.	2.1	8
11	Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs. Oncology Reports, 2014, 31, 1437-1444.	1.2	6
12	Fast DNA Vaccination Strategy Elicits a Stronger Immune Response Dependent on CD8+CD11c+ Cell Accumulation. Frontiers in Oncology, 2021, 11, 752444.	1.3	2
13	Preclinical Safety and Biodistribution in Mice Following Single-Dose Intramuscular Inoculation of Tumor DNA Vaccine by Electroporation. Human Gene Therapy, 2022, 33, 757-764.	1.4	1